Please use this identifier to cite or link to this item:
|Title:||Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion||Authors:||Ibrahim, Ahmad
|Affiliations:||Faculty of Medicine||Keywords:||LSHBT
|Issue Date:||2021||Part of:||Frontiers in oncology||Volume:||11||Abstract:||
COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 infection has apparently been devastating. In this article we present recommendations and proposals to reduce or to manage SARS-Cov-2 infection in the patients with myeloid and lymphoid hematological malignancies.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/5300||ISSN:||2234-943X||DOI:||10.3389/fonc.2021.564383||Open URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Jan 23, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.